Edgewise Therapeutics, Inc., (NASDAQ: EWTX), is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.
Location: United States, Colorado, Boulder
Employees: 11-50
Phone: +1 720-262-7002
Total raised: $145M
Founded date: 2017
Investors 6
| Date | Name | Website |
| 20.02.2021 | Logos Capi... | logoscapit... |
| - | US Venture... | usvp.com |
| 13.07.2025 | Foresite C... | foresiteca... |
| - | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.12.2020 | Series C | $95M | - |
| 17.09.2019 | Series B | $50M | - |
Mentions in press and media 23
| Date | Title | Description |
| 07.08.2026 | Edgewise ups R&D spending as pharma firm focuses on cardiovascular pipeline | Getting your Trinity Audio player ready... Edgewise Therapeutics Inc. (Nasdaq: EWTX) spent more on research and development in the second quarter of fiscal 2026 as the Boulder pharmaceutical company moves away from muscular-dystrophy drug c... |
| 16.07.2026 | Edgewise closes muscular-dystrophy biz sale in deal that could top $2.6M | Getting your Trinity Audio player ready... BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX) recently closed on a deal — one that could eventually be worth $2.65 billion and includes a drug pipeline led by sevasemten — that sends its musc... |
| 13.07.2026 | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset and expert team strengthen Servier's commitment to ... |
| 05.06.2026 | French pharma giant Servier buys Edgewise muscular dystrophy biz | Getting your Trinity Audio player ready... BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX) has offloaded its muscular-dystrophy business, which includes a drug pipeline led by sevasemten, to France-based international pharmaceutical com... |
| 05.06.2026 | Some Broomfield ballot drop-off boxes to be closed during primary election | Getting your Trinity Audio player ready... In Broomfield, four of the city’s seven ballot drop-off box locations will be closed for the upcoming primary election for surveillance equipment replacement, according to city officials. Broomfiel... |
| 05.06.2026 | First-time homebuyers face hurdles despite gradual improvement | Getting your Trinity Audio player ready... By Tim Henderson, Stateline.org The idea started with a sermon Micah Longmire heard at his Presbyterian church in Ogden, Utah, about the importance of grandparents in a child’s life. Longmire, now ... |
| 05.06.2026 | Operator of S&P 500 decides against fast-tracking ‘MegaCap’ IPOs into its stock indexes | Getting your Trinity Audio player ready... By ALEX VEIGA, AP Business Writer The operator of the S&P 500 says it has decided not to change its guidelines for when very large “MegaCap” companies are eligible for inclusion into its bevy o... |
| 11.11.2025 | Edgewise Therapeutics’ loss grows as R&D expenses increase | Edgewise Therapeutics Inc. (Nasdaq: EWTX), a Boulder-based biopharmaceutical company that develops therapies for muscle disease, reported a higher net loss for the third quarter. Already have an account Log In Flash Sale Standard Digital $3... |
| 07.08.2025 | Edgewise maintains strong cash balance in Q2 | Edgewise Therapeutics Inc., (Nasdaq: EWTX), a Boulder-based muscle-disease biopharmaceutical company, maintained a strong cash balance in the second quarter as it proceeds with trials for treatment of Duchenne and Becker muscular dystrophy.... |
| 08.11.2024 | Business | Edgewise boosts R&D spending with drug trials underway | Edgewise Therapeutics Inc. (Nasdaq: EWTX), a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending slightly in the third quarter of 2024 from the preceding quarter as key drug trials are und... |
Show more